New Insulin Therapy by Multiwave Bolus — EVANEWFIT2  

Type1diabetes Clinical Trial

Official title: Evaluation of Insulin Therapy by Multiwave Bolus Based on the Lipid and Protein Content in Addition to the Carbohydrates Content Compared to Insulin Therapy Based Only on the Carbohydrates Content in type1 Diabetes Treated by Insulin Pump

Status Recruiting

Clinical Trial Summary

The aim of the study is to evaluate the effect of insulin therapy when the bolus dose of insulin is calculated on the basis of protein and fat content in food intake, in addition to that of carbohydrates in T1D patients treated by insulin pump. The study is planned to recruit 150 patients with type1 diabetes already practicing functional insulin therapy based on carbohydrate counting in meals. We will therefore study the effect on continuous glucose measured by subcutaneous sensor, of meal bolus adjustments by comparing two groups of T1D patients:

• Groupe A takes into account the lipid and protein content in addition to the carbohydrate content

• Group B takes into account the carbohydrate content only At randomization, all patients receive dietary and adjustment of bolus doses instructions according to the randomization group. They have to apply these instructions for 3 months. At the end of 3 months, the study groups will be under glucose monitoring during two weeks in the Outpatient Clinic but returns to the investigational site in hospital to download data from the continuous measurement of glucose. In addition, we propose a period of extension similar to that of the main period, namely 3 months of application of dietetic and adaptation of bolus doses instructions and 2 weeks of continuous measurement of glucose.

During each 2 weeks period will be assessed specific glucose parameters in the post-prandial period over 4hours (glycemic sensor values in the glucose range between 70-140 mg / dl, glycemic sensor values in the glucose range between 140 -180 mg /dl and > 180 mg /dl) after taking each meal during the 13 days of Glucose Continuous Measurement (GCM), average daily glucose per meal, average blood glucose over the 13-day period after each meal.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type1diabetes

• NCT number: NCT03311516
• Study type: Interventional
• Source: Central Hospital, Nancy, France
• Contact: SIHAM BENZIRAR
• Phone: 0033383155028
• Email: s.benzirar@chru-nancy.fr
• Status: Recruiting
• Phase: N/A
• Start date: October 10, 2019
• Completion date: June 2021